RETRACTED ARTICLE: MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel

Yan, Jie; Shi, Litong; Lin, Shan; Li, Yi

doi:10.1080/21655979.2021.1938497

Cited by 17 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…YAP plays a central role in oncogenic processes, functioning as a proto-oncogene that is overexpressed in many tumors [ 47–49 ]. In addition, patients with BC displaying high YAP activity appeared to have a higher overall positive prognosis, leading to the belief that YAP might act as a tumor suppressor in breast cancer [ 50–53 ].…”

Section: Discussionmentioning

confidence: 99%

A high level of the long non-coding RNA MCF2L-AS1 is associated with poor prognosis in breast cancer and MCF2L-AS1 activates YAP transcriptional activity to enhance breast cancer proliferation and metastasis

et al. 2022

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most prevalent gynecologic malignant tumors with a poor prognosis and the second leading cause of cancer-related deaths in women worldwide. In recent years, it has been shown that long non-coding RNA (lncRNA) plays an important role in the development of breast cancer (BC). An antisense lncRNA from the MCF2 cell line (MCF2L-AS1) has been discovered recently and has been shown to function in a variety of malignancies. However, its function as a regulator of BC development has yet to be determined. Herein, the bioinformatics study analysis showed that MCF2L-AS1 was frequently highly expressed in BC tumors, and this overexpression was associated with worse patient outcomes. BC cells’ proliferation, migration, and invasion are inhibited when MCF2L-AS1 is silenced, whereas the inverse is evident when MCF2L-AS1 is overexpressed. It was also observed that MCF2L-AS1 knockdown decreased carcinogenesis in xenograft tumor models. Furthermore, we discovered that MCF2L-AS1 could bind to and improve the transcription activity of the yes-associated protein (YAP). However, following YAP knockdown, this lncRNA’s ability to drive BC malignancy was considerably reduced. In conclusion, MCF2L-AS1 may represent a potential predictive biomarker in BC patients, as well as a key regulator of BC cell proliferation. It works through positive feedback processes involving direct YAP binding and subsequent modulation of intracellular gene expression. Our findings add to our understanding of MCF2L-AS1 regulation and its potential as a therapeutic target in patients with this fatal cancer type.

show abstract

Section: Discussionmentioning

confidence: 99%

A high level of the long non-coding RNA MCF2L-AS1 is associated with poor prognosis in breast cancer and MCF2L-AS1 activates YAP transcriptional activity to enhance breast cancer proliferation and metastasis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[16][17][18] In recent years, several studies have demonstrated that circulating miRNAs are useful biomarkers for detecting chemosensitivity in ESCC patients. [19][20][21][22] Recently, Kosaka and Ochiya et al proposed that tumor suppressor miRNAs are normally secreted from neighboring normal cells to function as an antitumor molecule, namely, the depletion of tumor suppressor miRNAs due to cancer cells may be supplied with exosomes from healthy cells. When normal cells are unable to meet this demand, cancer cells behave aggressively.…”

Section: Introductionmentioning

confidence: 99%

“…Numerous miRNAs have therefore been identified as blood‐based biomarkers 16–18 . In recent years, several studies have demonstrated that circulating miRNAs are useful biomarkers for detecting chemosensitivity in ESCC patients 19–22 …”

Section: Introductionmentioning

confidence: 99%

Plasma miR‐1254 as a predictive biomarker of chemosensitivity and a target of nucleic acid therapy in esophageal cancer

et al. 2023

View full text Add to dashboard Cite

This study investigated novel tumor suppressor microRNAs (miRNAs) that decrease in plasma and predict chemosensitivity to neoadjuvant chemotherapy (NAC) for esophageal squamous cell carcinoma (ESCC) and revealed their usefulness as novel therapeutic agents. We selected four miRNA candidates (miR‐323, 345, 409, and 1254) based on the microRNA microarray comparing pre‐treatment plasma levels in ESCC patients with high and low histopathological responses to NAC and an NCBI database review. Among these miRNA candidates, miR‐1254 was more highly elevated in pre‐treatment plasma of ESCC patients with a high histopathological response than in those with a low histopathological response (P = 0.0021, area under the receiver‐operating characteristic curve 0.7621). High plasma miR‐1254 levels tended to correlate with the absence of venous invasion (P = 0.0710) and were an independent factor predicting a higher response to chemotherapy (P = 0.0022, odds ratio 7.86) and better prognosis (P = 0.0235, hazard ratio 0.23). Overexpressing miR‐1254 in ESCC cells significantly enhanced chemosensitivity to cisplatin through the transcriptional regulation of ABCC1 in vitro. Moreover, increased plasma miR‐1254 levels by subcutaneous injection significantly improved responses to cisplatin in mice. Plasma miR‐1254 might be a useful biomarker for predicting responses to NAC, and the restoration of plasma miR‐1254 levels might improve chemosensitivity in ESCC.

show abstract

“…Yes1-associated transcriptional regulator (YAP1) was identified as an essential growth initiator or enhancers in several solid tumors, such as hepatocarcinoma, gastric cancer, and colorectal cancer [ 12 ]. YAP1 mediated progression, tumorigenesis, stemness, and chemoresistance in ESCC [ 13 – 16 ]. Post-transcription modifications (PTMs) of YAP1 at different sites, the most recognized of which is phosphorylation, play diverse roles in the turnover and spatial regulation of YAP1 [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

NEK2 promotes the migration and proliferation of ESCC via stabilization of YAP1 by phosphorylation at Thr-143

Wei

Ding

et al. 2022

Cell Commun Signal

View full text Add to dashboard Cite

Background Esophageal Squamous Cell Carcinoma (ESCC) was characterized as a regional-prevalent and aggressive tumor with high morbidity and mortality. NIMA-related kinase 2 (NEK2) is an interesting oncogene, the alteration of which leads to patients-beneficial outcomes. We aimed to explore the role of NEK2 in ESCC and excavate its mechanism. Methods RNA-seq data were downloaded from TCGA and GEO and analyzed by R software. The protein levels were detected by immunohistochemistry (IHC) or western blot (WB), and mRNA expression was detected by qRT-PCR. The in vitro role of proliferation and migration was detected by Transwell migration assay and by colony formation assay, respectively. The in vivo roles were explored using a subcutaneous xenograft tumor model, where immunofluorescence (IF) and IHC were employed to investigate expression and localization. The interaction between proteins was detected by immunoprecipitation. The stability of proteins was measured by WB in the presence of cycloheximide. Results A higher level of NEK2 was found in ESCC than normal esophageal epithelia in GEO, TCGA, and tissue microarray, which was associated with worse prognoses. The NEK2 knockdown impaired the proliferation and migration of ESCC, which also downregulated YAP1 and EMT markers like N-cadherin and Vimentin in vitro. On the contrary, NEK2 overexpression enhanced the migration of ESCC and elevated the levels of YAP1, N-cadherin, and Vimentin. Additionally, the overexpression of YAP1 in NEK2 knocked down ESCCs partly rescued the corresponding decrease in migration. The knockdown of NEK2 played an anti-tumor role in vivo and was accompanied by a lower level and nucleus shuffling of YAP1. In mechanism, NEK2 interacted with YAP1 and increased the stability of both endogenous and exogenous YAP1 by preventing ubiquitination. Moreover, the computer-predicted phosphorylation site of YAP1, Thr-143, reduced the ubiquitination of HA-YAP1, strengthened its stability, and thus influenced the migration in vitro. Conclusions NEK2 is a prognostic oncogene highly expressed in ESCC and promotes the progression of ESCC in vitro and in vivo. Mechanistically, NEK2-mediated phosphorylation of YAP1 at Thr-143 protects it from proteasome degradation and might serve as a promising therapeutic target in ESCC.

show abstract

RETRACTED ARTICLE: MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel

Cited by 17 publications

References 33 publications

A high level of the long non-coding RNA MCF2L-AS1 is associated with poor prognosis in breast cancer and MCF2L-AS1 activates YAP transcriptional activity to enhance breast cancer proliferation and metastasis

A high level of the long non-coding RNA MCF2L-AS1 is associated with poor prognosis in breast cancer and MCF2L-AS1 activates YAP transcriptional activity to enhance breast cancer proliferation and metastasis

Plasma miR‐1254 as a predictive biomarker of chemosensitivity and a target of nucleic acid therapy in esophageal cancer

NEK2 promotes the migration and proliferation of ESCC via stabilization of YAP1 by phosphorylation at Thr-143

Contact Info

Product

Resources

About